BioNxt Solutions Inc. (FRA:BXT)

Market Cap	42.96M +3.5%
Revenue (ttm)	9.68K -62.3%
Net Income	-3.78M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,576
Average Volume	10,252
Open	0.3580
Previous Close	0.3600
Day's Range	0.3300 - 0.3720
52-Week Range	0.2340 - 0.6900
Beta	n/a
RSI	42.34
Earnings Date	Apr 2, 2026

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BXT

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial numbers in CAD